vs

Side-by-side financial comparison of AMERICAN SHARED HOSPITAL SERVICES (AMS) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.

AMERICAN SHARED HOSPITAL SERVICES is the larger business by last-quarter revenue ($7.7M vs $5.0M, roughly 1.5× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -8.2%, a 2.5% gap on every dollar of revenue. On growth, cbdMD, Inc. posted the faster year-over-year revenue change (-1.9% vs -14.8%). cbdMD, Inc. produced more free cash flow last quarter ($-977.3K vs $-2.7M). Over the past eight quarters, AMERICAN SHARED HOSPITAL SERVICES's revenue compounded faster (21.7% CAGR vs 7.1%).

American Shared Hospital Services offers turnkey outsourced solutions for advanced radiotherapy, stereotactic radiosurgery and diagnostic imaging equipment to healthcare facilities. It eliminates high upfront capital costs for hospitals, operates primarily across North America, and also serves Latin America and select Asia-Pacific markets, catering to both public and private hospital segments.

cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.

AMS vs YCBD — Head-to-Head

Bigger by revenue
AMS
AMS
1.5× larger
AMS
$7.7M
$5.0M
YCBD
Growing faster (revenue YoY)
YCBD
YCBD
+12.9% gap
YCBD
-1.9%
-14.8%
AMS
Higher net margin
YCBD
YCBD
2.5% more per $
YCBD
-5.6%
-8.2%
AMS
More free cash flow
YCBD
YCBD
$1.7M more FCF
YCBD
$-977.3K
$-2.7M
AMS
Faster 2-yr revenue CAGR
AMS
AMS
Annualised
AMS
21.7%
7.1%
YCBD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AMS
AMS
YCBD
YCBD
Revenue
$7.7M
$5.0M
Net Profit
$-631.0K
$-283.1K
Gross Margin
11.7%
59.8%
Operating Margin
-18.1%
-5.7%
Net Margin
-8.2%
-5.6%
Revenue YoY
-14.8%
-1.9%
Net Profit YoY
52.5%
-1975.7%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMS
AMS
YCBD
YCBD
Q4 25
$7.7M
$5.0M
Q3 25
$7.2M
$4.7M
Q2 25
$7.1M
$4.6M
Q1 25
$6.1M
$4.7M
Q4 24
$9.1M
$5.1M
Q3 24
$7.0M
$4.6M
Q2 24
$7.1M
$5.2M
Q1 24
$5.2M
$4.4M
Net Profit
AMS
AMS
YCBD
YCBD
Q4 25
$-631.0K
$-283.1K
Q3 25
$-17.0K
$-680.0K
Q2 25
$-280.0K
$-895.3K
Q1 25
$-625.0K
$-480.8K
Q4 24
$-1.3M
$15.1K
Q3 24
$-207.0K
$-152.8K
Q2 24
$3.6M
$459.7K
Q1 24
$119.0K
$-3.0M
Gross Margin
AMS
AMS
YCBD
YCBD
Q4 25
11.7%
59.8%
Q3 25
22.1%
58.8%
Q2 25
23.1%
61.5%
Q1 25
15.4%
62.3%
Q4 24
35.3%
66.5%
Q3 24
19.6%
53.9%
Q2 24
35.0%
65.8%
Q1 24
41.1%
59.0%
Operating Margin
AMS
AMS
YCBD
YCBD
Q4 25
-18.1%
-5.7%
Q3 25
-4.8%
-14.5%
Q2 25
-7.7%
-19.6%
Q1 25
-21.3%
-10.2%
Q4 24
-20.2%
-1.7%
Q3 24
-12.7%
-6.9%
Q2 24
-0.0%
-7.4%
Q1 24
-1.6%
-35.4%
Net Margin
AMS
AMS
YCBD
YCBD
Q4 25
-8.2%
-5.6%
Q3 25
-0.2%
-14.4%
Q2 25
-4.0%
-19.4%
Q1 25
-10.2%
-10.1%
Q4 24
-14.6%
0.3%
Q3 24
-3.0%
-3.4%
Q2 24
51.0%
8.9%
Q1 24
2.3%
-68.8%
EPS (diluted)
AMS
AMS
YCBD
YCBD
Q4 25
$-0.09
Q3 25
$0.00
Q2 25
$-0.04
Q1 25
$-0.10
Q4 24
$-0.21
Q3 24
$-0.03
Q2 24
$0.55
$-0.15
Q1 24
$0.02
$-1.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMS
AMS
YCBD
YCBD
Cash + ST InvestmentsLiquidity on hand
$3.5M
$3.4M
Total DebtLower is stronger
$17.4M
Stockholders' EquityBook value
$24.0M
$9.0M
Total Assets
$55.5M
$11.8M
Debt / EquityLower = less leverage
0.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMS
AMS
YCBD
YCBD
Q4 25
$3.5M
$3.4M
Q3 25
$5.1M
$2.3M
Q2 25
$11.1M
$1.1M
Q1 25
$11.2M
$1.8M
Q4 24
$11.0M
$2.0M
Q3 24
$13.8M
$2.5M
Q2 24
$14.2M
$2.4M
Q1 24
$12.8M
$2.1M
Total Debt
AMS
AMS
YCBD
YCBD
Q4 25
$17.4M
Q3 25
$18.2M
Q2 25
$19.1M
Q1 25
$19.9M
Q4 24
$20.4M
Q3 24
$14.4M
Q2 24
$15.1M
Q1 24
$15.6M
Stockholders' Equity
AMS
AMS
YCBD
YCBD
Q4 25
$24.0M
$9.0M
Q3 25
$24.6M
$7.2M
Q2 25
$24.5M
$6.1M
Q1 25
$24.6M
$665.8K
Q4 24
$25.2M
$1.8M
Q3 24
$26.4M
$2.0M
Q2 24
$26.5M
$3.0M
Q1 24
$22.8M
$3.1M
Total Assets
AMS
AMS
YCBD
YCBD
Q4 25
$55.5M
$11.8M
Q3 25
$59.6M
$10.4M
Q2 25
$63.5M
$9.9M
Q1 25
$63.3M
$10.9M
Q4 24
$60.2M
$11.5M
Q3 24
$63.3M
$10.6M
Q2 24
$60.8M
$13.8M
Q1 24
$50.1M
$14.6M
Debt / Equity
AMS
AMS
YCBD
YCBD
Q4 25
0.72×
Q3 25
0.74×
Q2 25
0.78×
Q1 25
0.81×
Q4 24
0.81×
Q3 24
0.54×
Q2 24
0.57×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMS
AMS
YCBD
YCBD
Operating Cash FlowLast quarter
$-704.0K
$-812.5K
Free Cash FlowOCF − Capex
$-2.7M
$-977.3K
FCF MarginFCF / Revenue
-34.8%
-19.5%
Capex IntensityCapex / Revenue
25.7%
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.5M
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMS
AMS
YCBD
YCBD
Q4 25
$-704.0K
$-812.5K
Q3 25
$1.7M
$-240.7K
Q2 25
$-372.0K
$-704.2K
Q1 25
$2.5M
$-189.5K
Q4 24
$274.0K
$-317.9K
Q3 24
$472.0K
$167.4K
Q2 24
$1.3M
$289.8K
Q1 24
$-1.9M
$-704.1K
Free Cash Flow
AMS
AMS
YCBD
YCBD
Q4 25
$-2.7M
$-977.3K
Q3 25
$-2.0M
$-243.6K
Q2 25
$-2.3M
$-705.7K
Q1 25
$-1.5M
$-205.0K
Q4 24
$-4.4M
$-482.3K
Q3 24
$-407.0K
$157.4K
Q2 24
$70.0K
Q1 24
$-3.0M
$-708.7K
FCF Margin
AMS
AMS
YCBD
YCBD
Q4 25
-34.8%
-19.5%
Q3 25
-28.3%
-5.2%
Q2 25
-32.1%
-15.3%
Q1 25
-24.7%
-4.3%
Q4 24
-48.4%
-9.4%
Q3 24
-5.8%
3.5%
Q2 24
1.0%
Q1 24
-58.4%
-16.2%
Capex Intensity
AMS
AMS
YCBD
YCBD
Q4 25
25.7%
3.3%
Q3 25
51.6%
0.1%
Q2 25
26.9%
0.0%
Q1 25
65.7%
0.3%
Q4 24
51.4%
3.2%
Q3 24
12.6%
0.2%
Q2 24
17.2%
0.0%
Q1 24
22.7%
0.1%
Cash Conversion
AMS
AMS
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-21.06×
Q3 24
Q2 24
0.36×
0.63×
Q1 24
-15.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMS
AMS

Direct Patient Services$4.0M51%
Rental Income From Medical Services$2.7M35%
Pbrt Services$1.2M15%

YCBD
YCBD

Sales Channel Directly To Consumer$3.6M72%
Sales Channel Through Intermediary$1.4M28%

Related Comparisons